Market Overview:

The global amyotrophic lateral sclerosis treatment market size reached US$ 719.2 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 969.3 Million by 2028, exhibiting a growth rate (CAGR) of 4.9% during 2023-2028.

Amyotrophic Lateral Sclerosis (ALS) Treatment refers to a degenerative disease that affects the nerve cells in the spinal cord and brain, resulting in loss of muscle control. It primarily occurs due to gene mutation, disorganized immune response, chemical imbalance, etc. Some of the common symptoms of ALS include muscle stiffness, twitching of the muscles, weakness in the legs or arms, cognitive and behavioral changes, trouble in swallowing, slurred speech, etc. The diagnosis of ALS relies on medical history, physical examination, electrodiagnostic testing, and neuroimaging.

Amyotrophic Lateral Sclerosis Treatment Market Trends:

The rising incidences of neurodegenerative disorders due to changing lifestyle patterns and hectic schedules of the individuals are primarily driving the Amyotrophic Lateral Sclerosis Treatment treatment market. Besides this, the expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth. Furthermore, several NGOs and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted and symptomatic treatment options for ALS is acting as a significant growth-inducing factor. Moreover, the elevating focus on clinical trials and faster approval of oral drugs for ALS treatment is also bolstering the market growth. Moreover, the increasing strategic collaborations among various research institutes to develop innovative treatment procedures that aim at enhancing muscle function, immune modulation, and neuroprotection are further catalyzing the global market. In the coming years, the continuous upgradation of healthcare infrastructures along with elevating penetration of refurbishment policies will continue to drive the global amyotrophic lateral sclerosis (ALS) treatment market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global amyotrophic lateral sclerosis treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on ALS type, drug type, diagnosis type, treatment and distribution channel.

Breakup by ALS Type:

• Sporadic ALS
• Familial ALS
   

Breakup by Drug Type:

• Marketed Drugs
• Emerging Drugs
   

Breakup by Diagnosis Type:

• Electromyogram
• MRI
• Blood and Urine Tests
• Spinal Tap
• Muscle Biopsy
   

Breakup by Treatment:

• Medication
• Stem Cell Therapy
• Others 
   

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Ascend Pharmaceuticals LLC, BrainStorm Cell Therapeutics Inc., Corestem Inc., Cytokinetics Inc., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ITF Pharma (Italfarmaco S.p.A), Mitsubishi Chemical Group Corpotion, Revalesio Corporation and Treeway B.V.

Report Coverage: